Similar articles for PMID: 29777009

Year	Number of Results
1997	1
2002	2
2003	1
2004	1
2005	1
2006	3
2007	1
2008	4
2009	2
2010	3
2011	4
2012	6
2013	7
2014	6
2015	8
2016	13
2017	11
2018	6
2019	3
2022	2
2023	2
2024	0

1

Feasibility of CXCR4-Directed Radioligand Therapy in Advanced Diffuse Large B-Cell Lymphoma.

Lapa C, Hänscheid H, Kircher M, Schirbel A, Wunderlich G, Werner RA, Samnick S, Kotzerke J, Einsele H, Buck AK, Wester HJ, Grigoleit GU. Lapa C, et al. J Nucl Med. 2019 Jan;60(1):60-64. doi: 10.2967/jnumed.118.210997. Epub 2018 May 18. J Nucl Med. 2019. PMID: 29777009 Free article.

2

C-X-C Motif Chemokine Receptor 4-Targeted Radioligand Therapy in Patients with Advanced T-Cell Lymphoma.

Buck AK, Grigoleit GU, Kraus S, Schirbel A, Heinsch M, Dreher N, Higuchi T, Lapa C, Hänscheid H, Samnick S, Einsele H, Serfling SE, Werner RA. Buck AK, et al. J Nucl Med. 2023 Jan;64(1):34-39. doi: 10.2967/jnumed.122.264207. Epub 2022 Jun 23. J Nucl Med. 2023. PMID: 35738903 Free PMC article.

3

Side Effects of CXC-Chemokine Receptor 4-Directed Endoradiotherapy with Pentixather Before Hematopoietic Stem Cell Transplantation.

Maurer S, Herhaus P, Lippenmeyer R, Hänscheid H, Kircher M, Schirbel A, Maurer HC, Buck AK, Wester HJ, Einsele H, Grigoleit GU, Keller U, Lapa C. Maurer S, et al. J Nucl Med. 2019 Oct;60(10):1399-1405. doi: 10.2967/jnumed.118.223420. Epub 2019 Mar 8. J Nucl Med. 2019. PMID: 30850502 Free PMC article.

4

CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed Multiple Myeloma.

Lapa C, Herrmann K, Schirbel A, Hänscheid H, Lückerath K, Schottelius M, Kircher M, Werner RA, Schreder M, Samnick S, Kropf S, Knop S, Buck AK, Einsele H, Wester HJ, Kortüm KM. Lapa C, et al. Theranostics. 2017 Apr 8;7(6):1589-1597. doi: 10.7150/thno.19050. eCollection 2017. Theranostics. 2017. PMID: 28529638 Free PMC article.

5

Clinical significance of chemokine receptor CXCR4 and mammalian target of rapamycin (mTOR) expression in patients with diffuse large B-cell lymphoma.

Xu ZZ, Shen JK, Zhao SQ, Li JM. Xu ZZ, et al. Leuk Lymphoma. 2018 Jun;59(6):1451-1460. doi: 10.1080/10428194.2017.1379077. Epub 2017 Sep 27. Leuk Lymphoma. 2018. PMID: 28952842

6

Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial.

Johnston PB, LaPlant B, McPhail E, Habermann TM, Inwards DJ, Micallef IN, Colgan JP, Nowakowski GS, Ansell SM, Witzig TE. Johnston PB, et al. Lancet Haematol. 2016 Jul;3(7):e309-16. doi: 10.1016/S2352-3026(16)30040-0. Epub 2016 Jun 5. Lancet Haematol. 2016. PMID: 27374464 Free PMC article. Clinical Trial.

7

Clinical significance of nuclear factor κB and chemokine receptor CXCR4 expression in patients with diffuse large B-cell lymphoma who received rituximab-based therapy.

Shin HC, Seo J, Kang BW, Moon JH, Chae YS, Lee SJ, Lee YJ, Han S, Seo SK, Kim JG, Sohn SK, Park TI. Shin HC, et al. Korean J Intern Med. 2014 Nov;29(6):785-92. doi: 10.3904/kjim.2014.29.6.785. Epub 2014 Oct 31. Korean J Intern Med. 2014. PMID: 25378977 Free PMC article.

8

Consolidation anti-CD22 fractionated radioimmunotherapy with ⁹⁰Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial.

Kraeber-Bodere F, Pallardy A, Maisonneuve H, Campion L, Moreau A, Soubeyran I, Le Gouill S, Tournilhac O, Daguindau E, Jardel H, Morineau N, Bouabdallah K, Gyan E, Moles MP, Gressin R, Berthou C, Sadot S, Moreau P, Deau B, Bodet-Milin C, Cazeau AL, Garin E, Salaun PY, Vuillez JP, Gouilleux-Gruart V, Barbet J, Wegener WA, Goldenberg DM, Lamy T, Soubeyran P. Kraeber-Bodere F, et al. Lancet Haematol. 2017 Jan;4(1):e35-e45. doi: 10.1016/S2352-3026(16)30168-5. Epub 2016 Dec 8. Lancet Haematol. 2017. PMID: 27964867 Clinical Trial.

9

C-X-C Chemokine Receptor 4 in Diffuse Large B Cell Lymphoma: Achievements and Challenges.

Du H, Gao L, Luan J, Zhang H, Xiao T. Du H, et al. Acta Haematol. 2019;142(2):64-70. doi: 10.1159/000497430. Epub 2019 May 16. Acta Haematol. 2019. PMID: 31096215 Free article. Review.

10

Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.

Mappa S, Marturano E, Licata G, Frezzato M, Frungillo N, Ilariucci F, Stelitano C, Ferrari A, Sorarù M, Vianello F, Baldini L, Proserpio I, Foppoli M, Assanelli A, Reni M, Caligaris-Cappio F, Ferreri AJ. Mappa S, et al. Hematol Oncol. 2013 Sep;31(3):143-50. doi: 10.1002/hon.2037. Epub 2012 Nov 14. Hematol Oncol. 2013. PMID: 23161567

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

72 results

Results by year